Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (101-110 of 250) with videos related to

Pageof 25
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 6, 2017
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyGavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, et al.
European Radiology|May 28, 2016
Altered signal intensity of active enhancing inflammatory lesions using post-contrast double inversion recovery MR sequenceJérôme Hodel, Sammy Badr, Olivier Outteryck, et al.
Neurology and Therapy|March 15, 2024
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from FranceJonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, et al.
Brain Sciences|February 25, 2022
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive PhenotypeBruno Brochet, Pierre Clavelou, Gilles Defer, et al.
Interdisciplinary Perspectives on Infectious Diseases|January 19, 2012
Changes Related to Age in Natural and Acquired Systemic Self-IgG Responses in MalariaRomuald Dassé, Didier Lefranc, Sylvain Dubucquoi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 3, 2018
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY studyGavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, et al.
European Journal of Medicinal Chemistry|July 31, 2017
Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligandsMarion Donnier-Maréchal, Pascal Carato, Paul-Emmanuel Larchanché, et al.
Multiple Sclerosis and Related Disorders|October 18, 2024
Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)Cécile Donzé, Claude Mekies, Géraud Paillot, et al.
Multiple Sclerosis and Related Disorders|March 20, 2019
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosisGiancarlo Comi, Stuart Cook, Gavin Giovannoni, et al.
The Journal of Rheumatology|March 3, 2004
Autoantibodies against alpha-fodrin in Sjögren's syndrome with neurological manifestationsJérôme de Seze, Sylvain Dubucquoi, Anne-Laure Fauchais, et al.
Pageof 25

Showing results (101-110 of 250) with videos related to

Sort By:
Pageof 25
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 6, 2017
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyGavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, et al.
European Radiology|May 28, 2016
Altered signal intensity of active enhancing inflammatory lesions using post-contrast double inversion recovery MR sequenceJérôme Hodel, Sammy Badr, Olivier Outteryck, et al.
Neurology and Therapy|March 15, 2024
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from FranceJonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, et al.
Brain Sciences|February 25, 2022
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive PhenotypeBruno Brochet, Pierre Clavelou, Gilles Defer, et al.
Interdisciplinary Perspectives on Infectious Diseases|January 19, 2012
Changes Related to Age in Natural and Acquired Systemic Self-IgG Responses in MalariaRomuald Dassé, Didier Lefranc, Sylvain Dubucquoi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 3, 2018
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY studyGavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, et al.
European Journal of Medicinal Chemistry|July 31, 2017
Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligandsMarion Donnier-Maréchal, Pascal Carato, Paul-Emmanuel Larchanché, et al.
Multiple Sclerosis and Related Disorders|October 18, 2024
Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)Cécile Donzé, Claude Mekies, Géraud Paillot, et al.
Multiple Sclerosis and Related Disorders|March 20, 2019
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosisGiancarlo Comi, Stuart Cook, Gavin Giovannoni, et al.
The Journal of Rheumatology|March 3, 2004
Autoantibodies against alpha-fodrin in Sjögren's syndrome with neurological manifestationsJérôme de Seze, Sylvain Dubucquoi, Anne-Laure Fauchais, et al.
Pageof 25